Redeye comments on Annexin's Q1 report and recent events in the company. We have made a handful of adjustments to our model surrounding timelines, financing, IP, and FX, which have led to a downward revision of the valuation range. We believe Annexin is well-positioned to secure a licensing agreement, supported by the compelling phase IIa results. This update also provides a short case recap.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/